Merck Serono recently held a cornerstone ceremony at the Merck Serono Biotech Center (MSBC), its production site in Corsiersur-Vevey, Switzerland, to mark the expansion of the site. The expansion will enable the production of greater quantities of Erbitux, in order to meet growing patient needs, as well as the production of potential future treatments in autoimmune and inflammatory diseases currently under clinical development. Erbitux, Merck Serono’s monoclonal antibody for the targeted treatme...